THYROCARE · NSE
Thyrocare Technologies Limited
₹528.45
+4.67% (+₹23.6)
Prev. close
₹504.85
Volume
90,96,697
Delivery %
6.8%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Thyrocare Technologies with a target price of ₹600, recommending a buy at ₹542 with a stop loss at ₹515 for t…” | Hitesh TailorChoice Equity Broking | Thyrocare Technologies | NOT TRIGGERED | |
| “Bullish on Thyrocare Technologies for the near term, recommending a buy at ₹1,568 with a target of ₹1,756 and a stop los…” | Kunal KambleBonanza Portfolio | Thyrocare Technologies Ltd | MISS | |
| “ICICI Securities recommends buying Thyrocare Technologies with a target price of ₹1560.” | ICICI Securities AnalysisICICI Securities | Thyrocare Technologies | HIT | |
| “Bullish on Thyrocare Technologies Ltd, recommending a buy at ₹889 with a stop loss at ₹858 for a target price of ₹950. T…” | Sumeet BagadiaChoice Equity Broking | Thyrocare Technologies Ltd | PENDING | |
| “ICICI Securities recommends buying Thyrocare Technologies with a target price of ₹1,000. The call is based on the compan…” | ICICI Securities AnalysisICICI Securities | Thyrocare Technologies | PENDING |
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends adding Thyrocare Technologies, identifying it as a standout small-cap with 223% upside potential, the highest…” | InCred Equities AnalysisInCred Equities | Thyrocare Technologies Ltd | — | |
| “Bullish on Thyrocare Technologies, expecting the ongoing bullish momentum to persist and test the resistance zone of ₹51…” | Asit C. Mehta Investment Intermediates AnalysisAsit C. Mehta Investment Intermediates | Thyrocare Technologies | — | |
| “Recommends an 'Add' rating on Thyrocare Tech for June 2025, supported by a favorable monsoon forecast and robust GVA gro…” | InCred Equities AnalysisInCred Equities | Thyrocare Technologies Ltd | — |
Fundamentals
About Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Rahul Franklin Guha
Headquarters
Navi Mumbai
Employees
1,906
Website
thyrocare.comExchange
View on NSE ↗Key stats
Market cap
₹7,886.64 Cr
P/E ratio (TTM)
55.2
Dividend yield
1.93%
EPS (TTM)
₹8.97
Beta (1Y · daily vs NIFTY 50)
0.52
Beta (5Y · monthly vs NIFTY 50)
0.98
Shares float
8.11 Cr
EPS · quarter ended Sept 2026
₹0.96
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹494.62 Cr | ₹588.86 Cr | ₹526.67 Cr | ₹571.88 Cr | ₹687.35 Cr | ₹829.04 Cr | |
EBITDA | ₹183.68 Cr | ₹264.14 Cr | ₹129.65 Cr | ₹146.80 Cr | ₹205.19 Cr | ₹272.87 Cr |
| ₹113.14 Cr | ₹176.14 Cr | ₹64.49 Cr | ₹70.76 Cr | ₹91.51 Cr | ₹163.04 Cr | |
Diluted EPS | ₹7.12 | ₹11.08 | ₹4.05 | ₹4.47 | ₹5.69 | ₹10.24 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹545.80 Cr | ₹607.66 Cr | ₹632.72 Cr | ₹643.88 Cr | ₹692.75 Cr | ₹747.22 Cr | |
| ₹8.49 Cr | ₹20.70 Cr | ₹23.31 Cr | ₹42.34 Cr | ₹24.68 Cr | ₹50.69 Cr | |
Stockholders' equity | ₹427.28 Cr | ₹526.57 Cr | ₹534.30 Cr | ₹526.77 Cr | ₹546.75 Cr | ₹585.50 Cr |
Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹116.30 Cr | ₹266.99 Cr | ₹129.31 Cr | ₹167.64 Cr | ₹179.91 Cr | ₹213.24 Cr | |
Investing cash flow | ₹-50.23 Cr | ₹-119.71 Cr | ₹-38.99 Cr | ₹-91.29 Cr | ₹-41.11 Cr | ₹-23.01 Cr |
| ₹-61.57 Cr | ₹-146.85 Cr | ₹-86.18 Cr | ₹-84.80 Cr | ₹-130.42 Cr | ₹-169.59 Cr | |
Capital expenditure | ₹-164.37 Cr | ₹-212.70 Cr | ₹-43.65 Cr | ₹-61.58 Cr | ₹-33.48 Cr | ₹-20.88 Cr |
End cash position | ₹13.20 Cr | ₹13.63 Cr | ₹17.77 Cr | ₹9.32 Cr | ₹17.68 Cr | ₹38.32 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Jun 22(3Q) | Sep 22–Sep 23(5Q) | Dec 23–Sep 24(4Q) | Dec 24–Sep 25(4Q) | Dec 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|
| Promoter | 71.22% | 71.18% | 71.14% | 71.11% | 71.06% | 60.93% | 60.92% |
| Public | 28.78% | 28.82% | 28.86% | 28.89% | 28.94% | 39.07% | 39.08% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Thyrocare Technologies Limited | ₹7,686.09 Cr | ₹495.5 | 53.8 | 13.13 | 27.8% | 0.09 | +20.7% | -63.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices